

PLASTIC & CHEMICALS 2023

Cyclo Therapeutics Inc. Rank 70 of 72











The relative strengths and weaknesses of Cyclo Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cyclo Therapeutics Inc. compared to the market average is the variable Cost of Revenues, increasing the Economic Capital Ratio by 939% points. The greatest weakness of Cyclo Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 2,507% points.

The company's Economic Capital Ratio, given in the ranking table, is -2,911%, being 2,810% points below the market average of -101%.

Input Variable	Value in 1000 USD
Assets, Current	4,159
Assets, Noncurrent	1.5
Cost of Revenues	0
Intangible Assets	0
Liabilities, Current	3,481
Liabilities, Noncurrent	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	7,998
Other Liabilities	0
Other Net Income	171
Other Revenues	1,376
Property, Plant and Equipment, Net	55
Selling, General and Administrative Expense	9,000

Output Variable	Value in 1000 USD
Liabilities	3,481
Assets	4,215
Expenses	16,998
Revenues	1,376
Stockholders Equity	735
Net Income	-15,451
Comprehensive Net Income	-15,451
Economic Capital Ratio	-2,911%

